Hillsdale Investment Management’s Travere Therapeutics TVTX Stock Holding History

Hillsdale Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.54M	Sell	167,900 -14,420	-8%	-$639K	0.22%	113
2026 Q1	$5.42M	Buy	182,320 +5,100	+3%	+$152K	0.15%	172
2025 Q4	$6.77M	Sell	177,220 -1,180	-0.7%	-$38.4K	0.19%	138
2025 Q3	$4.26M	Buy	178,400 +15,000	+9%	+$282K	0.13%	229
2025 Q2	$2.42M	Buy	+163,400	New	+$2.71M	0.09%	262
2021 Q1	–	Sell	-47,900	Closed	-$1.31M	–	682
2020 Q4	$1.31M	Hold	47,900	–	–	0.12%	168
2020 Q3	$884K	Sell	47,900 -400	-0.8%	-$7.78K	0.09%	206
2020 Q2	$986K	Buy	+48,300	New	+$769K	0.09%	180

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hillsdale Investment Management's TVTX Position: Q2 2026 in Review

Hillsdale Investment Management reduced its Travere Therapeutics (TVTX) stake by 7.9% in Q2 2026, selling an estimated $639K and leaving 167,900 shares worth $9.54M. The position accounts for 0.22% of the portfolio, ranked #113.

Hillsdale Investment Management first reported a position in TVTX in Q2 2020 and has held it in 8 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Hillsdale Investment Management held 167,900 shares of Travere Therapeutics worth $9.54M as of Q2 2026.
Hillsdale Investment Management sold 14,420 Travere Therapeutics shares in Q2 2026, an estimated $639K.
Travere Therapeutics made up 0.22% of Hillsdale Investment Management's portfolio in Q2 2026, its #113 holding.
Hillsdale Investment Management first reported a position in Travere Therapeutics in Q2 2020 and has held it in 8 quarters since.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.